Development of CpG-Oligodeoxynucleotides for effective activation of rabbit TLR9 mediated immune responses

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Chuang, Tsung Hsien ^a,b   Lai, Chao Yang ^a   Tseng, Ping Hui ^c   Yuan, Chiun Jye ^d   Hsu, Li Chung ^e  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CPG OLIGODEOXYNUCLEOTIDE; CYTOSINE; GUANINE; NJ85 PEPTIDE; PHOSPHOROTHIOIC ACID; THYMINE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VIRUS PROTEIN; CPG-OLIGONUCLEOTIDE; CYTOKINE; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; PEPTIDE; PHOSPHATE; PHOSPHORODITHIOIC ACID;

ADJUVANT THERAPY; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; IMMUNOSTIMULATION; LAGOVIRUS; MOUSE; NONHUMAN; NUCLEOTIDE MOTIF; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TOXICITY TESTING; ANIMAL; CHEMISTRY; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NUCLEOTIDE SEQUENCE; RABBIT; RABBIT HEMORRHAGIC DISEASE VIRUS; SPLEEN; T LYMPHOCYTE;

ORYCTOLAGUS CUNICULUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; BASE SEQUENCE; CYTOKINES; HEK293 CELLS; HEMORRHAGIC DISEASE VIRUS, RABBIT; HUMANS; IMMUNOGLOBULIN M; LYMPHOCYTE ACTIVATION; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDES; PHOSPHATES; RABBITS; SPLEEN; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 9;

EID: 84907486110     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108808     Document Type: Article

References (46)

1. Imler JL, Hoffmann JA (2001) Toll receptors in innate immunity. Trends Cell Biol 11: 304-311.
2. Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20: 197-216.
3. Kawai T, Akira S (2005) Pathogen recognition with Toll-like receptors. Curr Opin Immunol 17: 338-344.
4. Moresco EM, LaVine D, Beuder B (2011) Toll-like receptors. Curr Biol 21: R488-R493.
5. Chuang TH, Ulevitch RJ (2001) Identification of hTLRIO: a novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta 1518: 157-161.
6. Chuang TH, Ulevitch RJ (2000) Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw 11: 372-378.
7. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, et al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
8. Sato Y, Roman M, Tighe H, Lee D, Corr M, et al. (1996) Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273: 352-354.
9. Wagner H (1999) Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 73: 329-368.
10. Yamamoto S, Yamamoto T, Tokunaga T (2000) The discovery of immunos-timulatory DNA sequence. Springer Semin Immunopathol 22: 11 -19.
11. Pisetsky DS (2000) Mechanisms of immune stimulation by bacterial DNA. Springer Semin Immunopathol 22: 21-33.
12. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20: 709-760.
13. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
14. Severa M, Fitzgerald KA (2007) TLR-mediated activation of type I IFN during antiviral immune responses: fighting the batde to win the war. Curr Top Microbiol Immunol 316: 167-192.
15. Coll RC, O'Neill LA (2010) New insights into the regulation of signalling by toll-like receptors and nod-like receptors. J Innate Immun 2: 406-421.
16. Gosu V, Basith S, Kwon OP, Choi S (2012) Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signaling. Molecules 17: 13503 -13529.
17. Agrawal S, Kandimalla ER (2007) Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 35: 1461-1467.
18. Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13: 552-559.
19. Klinman DM, Klaschik S, Sato T, Tross D (2009) CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 61: 248-255.
20. De GE, Caproni E, Ulmer JB (2013) Vaccine adjuvants: mode of action. Front Immunol 4: 214.
21. Krieg AM (2012) CpG still rocks! Update on an accidental drug. Nucleic Acid Ther 22: 77-89.
22. Carrington AC, Secombes CJ (2006) A review of CpGs and their relevance to aquaculture. Vet Immunol Immunopathol 112: 87-101.
23. Chaung HC (2006) CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy. Int Immunopharmacol 6: 1586-1596.
24. Mutwiri G (2012) TER9 agonists: immune mechanisms and therapeutic potential in domestic animals. Vet Immunol Immunopathol 148: 85-89.
25. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, et al. (2001) Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 98: 9237-9242.
26. Chuang TH, Lee J, Kline L, Mathison JC, Ulevitch RJ (2002) Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol 71: 538-544.
27. Liu J, Xu C, Liu YL, Matsuo H, Hsieh RP, et al. (2012) Activation of rabbit TLR9 by different CpG-ODN optimized for mouse and human TLR9. Comp Immunol Microbiol Infect Dis 35: 443-451.
28. Rankin R, Pontarollo R, Ioannou X, Krieg AM, Hecker R, et al. (2001) CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev 11: 333-340.
29. Kerr PJ, Donnelly TM (2013) Viral infections of rabbits. Vet Clin North Am Exot Anim Pract 16: 437-468.
30. Atirantes J, van der Loo W, Le PJ, Esteves PJ (2012) Rabbit haemorrhagic disease (RHD) and rabbit haemorrhagic disease virus (RHDV): a review. Vet Res 43: 12.
31. Wang X, Xu F, Liu J, Gao B, Liu Y, et al. (2013) Atomic model of rabbit hemorrhagic disease virus by cryo-electron microscopy and crystallography. PLoS Pathog 9: e1003132.
32. Choe J, Kelker MS, Wilson IA (2005) Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 309: 581-585.
33. Govindaraj RG, Manavalan B, Basith S, Choi S (2011) Comparative analysis of species-specific ligand recognition in Toll-like receptor 8 signaling: a hypothesis. PLoS One 6: e25118.
34. Tanji H, Ohto U, Shibata T, Miyake K, Shimizu T (2013) Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science 339: 1426-1429.
35. Kang JY, LeeJO (2011) Structural biology of the Toll-like receptor family. Annu Rev Biochem 80: 917-941.
36. Botos I, Segal DM, Davies DR (2011) The structural biology of Toll-like receptors. Structure 19: 447-459.
37. Pan X, Yue J, Ding G, Li B, Liu X, et al. (2012) Leucine-rich repeat 11 of Toll-like receptor 9 can tighdy bind to CpG-containing oligodeoxynucleotides, and the positively charged residues are critical for the high affinity. J Biol Chem 287: 30596-30609.
38. Zhou W, Li Y, Pan X, Gao Y, Li B, et al. (2013) Toll-like receptor 9 interaction with CpG ODN - an in silico analysis approach. Theor Biol Med Model 10: 18.
39. Spieker-Polet H, Sethupathi P, Yam PC, Knight KL (1995) Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Proc Natl Acad Sci U S A 92: 9348-9352.
40. Rader C, Ritter G, Nathan S, Elia M, Gout I, et al. (2000) The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J Biol Chem 275: 13668-13676.
41. Rader C (2009) Generation and selection of rabbit antibody libraries by phage display. Methods Mol Biol 525: 101-128, xiv.
42. Weeratna RD, McCluskie MJ, Xu Y, Davis HL (2000) CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18: 1755-1762.
43. Stills HF Jr (2005) Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J 46: 280 -293.
44. Salem AK, Weiner GJ (2009) CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies. Adv Drug Deliv Rev 61: 193-194.
45. Wagner H (2009) The immunogenicity of CpG-antigen conjugates. Adv Drug Deliv Rev 61: 243-247.
46. Heegaard PM, Dedieu L, Johnson N, Le Potier MF, Mockey M, et al. (2011) Adjuvants and delivery systems in veterinary vaccinology: current state and future developments. Arch Virol 156: 183-202.